<DOC>
	<DOCNO>NCT00145314</DOCNO>
	<brief_summary>The main objective trial explore effect combine establish chemotherapy regimen ( FLOX ) , base 5-fluorouracil , folinic acid , oxaliplatin ( Eloxatin® ) , EGF receptor antibody cetuximab ( Erbitux® ) first-line treatment metastatic colorectal cancer . The trial investigate two regimen FLOX plus cetuximab , FLOX give continuously intermittently , compare standard FLOX without cetuximab .</brief_summary>
	<brief_title>FLOX Combination With Cetuximab First-line Treatment Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Histology stag disease : Histological proven adenocarcinoma colon rectum ; At least one measurable metastatic disease If one metastatic lesion SCEA elevation , histology mandatory ; Availability tumour sample EGFR assessment . General condition : Age &gt; 18 &lt; 75 year ; WHO performance status : life expectancy 3 month ; Adequate haematological function Adequate renal hepatic function Written inform consent Prior therapy : No prior chemotherapy advanced/metastatic disease ; No adjuvant chemotherapy last 6 month inclusion ; No previous oxaliplatin ; Prior current history : No current indication resection curative intent ; No evidence CNS metastasis ; No current infection , unresolved bowel obstruction subobstruction , uncontrolled Crohn 's disease ulcerative colitis ; No current history chronic diarrhoea ; No peripheral neuropathy ; No serious illness medical condition ( include contraindication 5 FU e.g . : angor , myocardial infarction within 6 month , contraindication monoclonal antibody ) ; No past concurrent history malignant neoplasm colorectal adenocarcinoma within past five year , except curatively treat non melanoma skin cancer situ carcinoma cervix ; Concomitant treatment : No concomitant ( within 4 week randomisation ) administration experimental drug investigation ; No concurrent treatment anticancer therapy ; Other : Not pregnant , breast feed Fertile patient must use adequate contraceptive Not include patient clearly intend withdraw study randomise willing arm patient regularly follow psychological , social , familiar geographic reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>FLOX</keyword>
	<keyword>Cetuximab</keyword>
</DOC>